Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in Systemic Lupus Erythematosus
NCT07760155Phase 2Not yet recruiting
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ESG206 in systemic lupus erythematosus (SLE), sponsored by Shanghai Escugen Biotechnology Co., Ltd.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ESG206
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07760155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760155.